Genetic, immunological and clinical risk factors for biliary strictures following liver transplantation

Liver International

Volumn 32, Issue 8, 2012, Pages 1253-1261

  Iacob, Speranta ^a,b   Cicinnati, Vito R ^a   Dechêne, Alexander ^a   Lindemann, Monika ^a   Heinemann, Falko M ^a   Rebmann, Vera ^a   Ferencik, Stanislav ^a   Sotiropoulos, Georgios C ^a   Popescu, Irinel ^b   Horn, Peter A ^a   Gerken, Guido ^a   Paul, Andreas ^a   Beckebaum, Susanne ^a,c  

^a UNIVERSITY HOSPITAL ESSEN   (Germany)

^b FUNDENI CLINICAL INSTITUTE   (Romania)

^c UNIVERSITY HOSPITAL MÜNSTER   (Germany)

Author keywords

Anastomotic biliary strictures; CCR5 32; Chemokine; CX3CR1; Ischaemic type biliary lesions; Liver transplantation

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CX3CR1; GAMMA INTERFERON; HLA ANTIGEN CLASS 2; INTERLEUKIN 10; INTERLEUKIN 6; LEUKOCYTE ANTIGEN;

ACUTE LIVER FAILURE; ADULT; ALLELE; ANTIBODY SCREENING; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE DUCT OBSTRUCTION; CONTROLLED STUDY; DONOR; GENETIC ASSOCIATION; GENETIC RISK; GENOTYPE; HEALTH SURVEY; HUMAN; IMMUNOLOGICAL PARAMETERS; IMMUNOSUPPRESSIVE TREATMENT; LIVER TRANSPLANTATION; LOSS OF FUNCTION MUTATION; MAJOR CLINICAL STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MULTIVARIATE ANALYSIS; POSTOPERATIVE COMPLICATION; PROTEIN POLYMORPHISM; RECIPIENT; RISK FACTOR; UNIVARIATE ANALYSIS;

ADULT; AGED; ANASTOMOSIS, SURGICAL; CHOLESTASIS; CROSS-SECTIONAL STUDIES; FEMALE; GPI-LINKED PROTEINS; GRAFT SURVIVAL; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; ISCHEMIA; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; MORBIDITY; POSTOPERATIVE COMPLICATIONS; PREDICTIVE VALUE OF TESTS; RECEPTORS, CCR2; RECEPTORS, CCR5; RECEPTORS, CHEMOKINE; RISK FACTORS;

EID: 84865173637     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02810.x     Document Type: Article

References (48)

1. Sharma S, Gurakar A, Jabbour N. Biliary strictures following liver transplantation: past, present and preventive strategies. Liver Transpl 2008; 14: 759-69.
2. Verdonk RC, Buis CI, Porte RJ, et al. Anastomotic biliary strictures after liver transplantation: causes and consequences. Liver Transpl 2006; 12: 726-35.
3. Verdonk RC, Buis CI, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 2: management, outcome, and risk factors for disease progression. Liver Transpl 2007; 13: 725-32.
4. Buis CI, Geuken E, Visser DS, et al. Altered bile composition after liver transplantation is associated with the development of nonanastomotic biliary strictures. J Hepatol 2009; 50: 69-79.
5. Op Den Dries S, Sutton ME, Lisman T, Porte RJ. Protection of bile ducts in liver transplantation: looking beyond ischemia. Transplantation 2011; 92: 373-9.
6. Strazzabosco M, Fabris L, Spirli C. Pathophysiology of cholangiopathies. J Clin Gastroenterol 2005; 39: S90-102.
7. Isse K, Harada K, Zen Y, et al. Fractalkine and CX3CR1 are involved in the recruitment of intraepithelial lymphocytes of intrahepatic bile ducts. Hepatology 2005; 41: 506-16.
8. Kruger B, Schroppel B, Murphy BT. Genetic polymorphisms and the fate of the transplanted organ. Transplant Rev (Orlando) 2008; 22: 131-40.
9. Moench C, Uhrig A, Lohse AW, Otto G. CC chemokine receptor 5delta32 polymorphism-a risk factor for ischemic-type biliary lesions following orthotopic liver transplantation. Liver Transpl 2004; 10: 434-9.
10. Op Den Dries S, Buis CI, Adelmeijer J, et al. The combination of primary sclerosing cholangitis and CCR5-Delta32 in recipients is strongly associated with the development of nonanastomotic biliary strictures after liver transplantation. Liver Int 2011; 31: 1102-9.
11. Castillo-Rama M, Castro MJ, Bernardo I, et al. Preformed antibodies detected by cytotoxic assay or multibead array decrease liver allograft survival: role of human leukocyte antigen compatibility. Liver Transpl 2008; 14: 554-62.
12. Muro M, Marin L, Miras M, et al. Liver recipients harbouring anti-donor preformed lymphocytotoxic antibodies exhibit a poor allograft survival at the first year after transplantation: experience of one centre. Transpl Immunol 2005; 14: 91-7.
13. Neumann UP, Guckelberger O, Langrehr JM, et al. Impact of human leukocyte antigen matching in liver transplantation. Transplantation 2003; 75: 132-7.
14. Oudshoorn M, Horn PA, Tilanus M, Yu N. Typing of potential and selected donors for transplant: methodology and resolution. Tissue Antigens 2007; 69(Suppl. 1): 10-2.
15. Heinemann FM. HLA genotyping and antibody characterization using the luminex multiplex technology. Transfus Med Hemother 2009; 36: 273-8.
16. Li S, Stratta RJ, Langnas AN, et al. Diffuse biliary tract injury after orthotopic liver transplantation. Am J Surg 1992; 164: 536-40.
17. Pirenne J, Monbaliu D, Aerts R, et al. Biliary strictures after liver transplantation: risk factors and prevention by donor treatment with epoprostenol. Transplant Proc 2009; 41: 3399-402.
18. Nakamura N, Nishida S, Neff GR, et al. Intrahepatic biliary strictures without hepatic artery thrombosis after liver transplantation: an analysis of 1, 113 liver transplantations at a single center. Transplantation 2005; 79: 427-32.
19. Moench C, Moench K, Lohse AW, Thies J, Otto G. Prevention of ischemic-type biliary lesions by arterial back-table pressure perfusion. Liver Transpl 2003; 9: 285-9.
20. Heidenhain C, Pratschke J, Puhl G, et al. Incidence of and risk factors for ischemic-type biliary lesions following orthotopic liver transplantation. Transpl Int 2010; 23: 14-22.
21. Buis CI, Verdonk RC, van der Jagt EJ, et al. Nonanastomotic biliary strictures after liver transplantation, part 1: radiological features and risk factors for early vs. late presentation. Liver Transpl 2007; 13: 708-18.
22. Licastro F, Candore G, Lio D, et al. Innate immunity and inflammation in ageing: a key for understanding age-related diseases. Immun Ageing 2005; 2: 8.
23. Heidenhain C, Puhl G, Moench C, Lautem A, Neuhaus P. Chemokine receptor-5delta32 mutation is no risk factor for ischemic-type biliary lesion in liver transplantation. J Transplant 2009; 2009: 436515.
24. Colvin BL, Thomson AW. Chemokines, their receptors, and transplant outcome. Transplantation 2002; 74: 149-55.
25. Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 1998; 187: 129-34.
26. Murai M, Yoneyama H, Harada A, et al. Active participation of CCR5(+)CD8(+) T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J Clin Invest 1999; 104: 49-57.
27. Andres PG, Beck PL, Mizoguchi E, et al. Mice with a selective deletion of the CC chemokine receptors 5 or 2 are protected from dextran sodium sulfate-mediated colitis: lack of CC chemokine receptor 5 expression results in a NK1.1 + lymphocyte-associated Th2-type immune response in the intestine. J Immunol 2000; 164: 6303-12.
28. Nozaki T, Amano H, Bickerstaff A, et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007; 179: 5238-45.
29. Bickerstaff A, Nozaki T, Wang JJ, et al. Acute humoral rejection of renal allografts in CCR5(-/-) recipients. Am J Transplant 2008; 8: 557-66.
30. Streetz KL, Wustefeld T, Klein C, Manns MP, Trautwein C. Mediators of inflammation and acute phase response in the liver. Cell Mol Biol (Noisy-le-grand) 2001; 47: 661-73.
31. Wu J, Ye S, Xu X, et al. Recipient outcomes after ABO-incompatible liver transplantation: a systematic review and meta-analysis. PLoS One 2011; 6: e16521.
32. Nakanuma Y, Sasaki M. Expression of blood group-related antigens in the intrahepatic biliary tree and hepatocytes in normal livers and various hepatobiliary diseases. Hepatology 1989; 10: 174-8.
33. Aladag M, Gurakar A, Camci C, et al. Compatible ABO mismatch and liver transplantation: a single center's experience. Exp Clin Transplant 2006; 4: 467-9.
34. Barone M, Avolio AW, Di LA, Burra P, Francavilla A. ABO blood group-related waiting list disparities in liver transplant candidates: effect of the MELD adoption. Transplantation 2008; 85: 844-9.
35. Busquets J, Castellote J, Torras J, et al. Liver transplantation across Rh blood group barriers increases the risk of biliary complications. J Gastrointest Surg 2007; 11: 458-63.
36. Cardarelli F, Pascual M, Tolkoff-Rubin N, et al. Prevalence and significance of anti-HLA and donor-specific antibodies long-term after renal transplantation. Transpl Int 2005; 18: 532-40.
37. Terasaki PI, Ozawa M, Castro R. Four-year follow-up of a prospective trial of HLA and MICA antibodies on kidney graft survival. Am J Transplant 2007; 7: 408-15.
38. Fontana M, Moradpour D, Aubert V, Pantaleo G, Pascual M. Prevalence of anti-HLA antibodies after liver transplantation. Transpl Int 2010; 23: 858-9.
39. Ge X, Ericzon BG, Nowak G, et al. Are preformed antibodies to biliary epithelial cells of clinical importance in liver transplantation? Liver Transpl 2003; 9: 1191-8.
40. Faure S, Meyer L, Costagliola D, et al. Rapid progression to AIDS in HIV+ individuals with a structural variant of the chemokine receptor CX3CR1. Science 2000; 287: 2274-7.
41. Karlmark KR, Zimmermann HW, Roderburg C, et al. The fractalkine receptor CXCR1 protects against liver fibrosis by controlling differentiation and survival of infiltrating hepatic monocytes. Hepatology 2010; 52: 1769-82.
42. Marasini B, Cossutta R, Selmi C, et al. Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension. Clin Dev Immunol 2005; 12: 275-9.
43. Brand S, Hofbauer K, Dambacher J, et al. Increased expression of the chemokine fractalkine in Crohn's disease and association of the fractalkine receptor T280M polymorphism with a fibrostenosing disease Phenotype. Am J Gastroenterol 2006; 101: 99-106.
44. Wasmuth HE, Zaldivar MM, Berres ML, et al. The fractalkine receptor CX3CR1 is involved in liver fibrosis due to chronic hepatitis C infection. J Hepatol 2008; 48: 208-15.
45. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nat Rev Immunol 2004; 4: 583-94.
46. Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. J Biol Chem 2002; 277: 35466-74.
47. Barbarin V, Arras M, Misson P, et al. Characterization of the effect of interleukin-10 on silica-induced lung fibrosis in mice. Am J Respir Cell Mol Biol 2004; 31: 78-85.
48. Wada K, Takada T, Kawarada Y, et al. Diagnostic criteria and severity assessment of acute cholangitis: Tokyo Guidelines. J Hepatobiliary Pancreat Surg 2007; 14: 52-8.